138117-79-0

Basic information

• Product Name: Benzoic acid, 4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl]amino]-, ethyl ester
• CAS NO: 138117-79-0
• Molecular Formula: C17H17N5O4
• Molecular Weight: 355.353
• Mol File: 138117-79-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl]amino]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl]amino]-, ethyl ester(138117-79-0)
• EPA Substance Registry System: Benzoic acid, 4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl]amino]-, ethyl ester(138117-79-0)

Safety Data

• Hazardous Substances Data: 138117-79-0(Hazardous Substances Data)

Upstream product

• 66224-66-6 adenine 
• 7083-40-1 3-(6-aminopurine-9-yl)-propionic acid ethyl ester 
• 34397-00-7 3-(1,6-DIHYDRO-6-OXO-9H-PURIN-9-YL)-PROPANOIC ACID 
• 94-09-7 p-aminoethylbenzoate 
• 95789-89-2 ethyl 3-(1,6-dihydro-6-oxo-9H-purin-9-yl)propanoate 

Relevant articles and documents

A new method for synthesis and angiogenic evaluation of leteprinim potassium and its novel analogs

We developed a novel pathway for the successful synthesis of leteprinim potassium 1, which is one of the candidate substances for treating Alzheimer's disease, and subsequently synthesized 4 types of corresponding novel derivatives 2-5 that have hypoxanthine or 2-chloro-6-aminopurine as the nucleobase. We then determined the angiogenic activity of these compounds by using human umbilical vein endothelial cells. Compounds 1-4 showed no angiogenic potencies judging from statistical analysis, student's t-test.

9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use

Novel bi-functional pharmaceutical compounds, particularly novel 9-substituted hypoxanthines of the general formula: STR1 where R is a neurologically active moiety, are described as pharmaceutical agents for treating neuroimmunologic disorders in mammals. Novel methods for the utilization of these compounds are also disclosed. These compounds exhibit uniquely dose-dependent, synergistic biological properties and are particularly useful for treating interrelated physiological systems.